JP2017019861A - Influenza virus infection inhibitor - Google Patents
Influenza virus infection inhibitor Download PDFInfo
- Publication number
- JP2017019861A JP2017019861A JP2016204967A JP2016204967A JP2017019861A JP 2017019861 A JP2017019861 A JP 2017019861A JP 2016204967 A JP2016204967 A JP 2016204967A JP 2016204967 A JP2016204967 A JP 2016204967A JP 2017019861 A JP2017019861 A JP 2017019861A
- Authority
- JP
- Japan
- Prior art keywords
- influenza virus
- nucleic acid
- pectin
- infection
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 56
- 239000003112 inhibitor Substances 0.000 title claims abstract description 48
- 230000009385 viral infection Effects 0.000 title claims abstract description 13
- 208000015181 infectious disease Diseases 0.000 claims abstract description 67
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 49
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 49
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 49
- 229920001277 pectin Polymers 0.000 claims abstract description 45
- 239000001814 pectin Substances 0.000 claims abstract description 45
- 235000010987 pectin Nutrition 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 102000053602 DNA Human genes 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 12
- 210000000214 mouth Anatomy 0.000 claims description 8
- 210000000936 intestine Anatomy 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960003752 oseltamivir Drugs 0.000 description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000002911 sialidase inhibitor Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000002605 large molecules Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- -1 methoxyl group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Landscapes
- Apparatus For Disinfection Or Sterilisation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
Abstract
Description
本発明は、インフルエンザウイルスの感染抑制剤に関する。 The present invention relates to an influenza virus infection inhibitor.
インフルエンザは、オルソミクソウイルス科に属するRNAウイルスであるインフルエンザウイルスに感染することにより生じる。インフルエンザはしばしば大流行し、多数の死者を出している。このため、インフルエンザの治療及び予防について様々な研究がなされている。インフルエンザの治療薬としてはオセルタミビル等が知られている。これらの治療薬は、インフルエンザウイルスが有するノイラミニダーゼを阻害し、インフルエンザウイルスが感染細胞から放出されにくくする。オセルタミビルは、インフルエンザの予防用にも使用されるが、インフルエンザウイルスの細胞への感染を直接阻害する作用は有していない。 Influenza is caused by infection with an influenza virus, an RNA virus belonging to the Orthomyxoviridae family. Influenza is often pandemic and causes many deaths. For this reason, various studies have been conducted on the treatment and prevention of influenza. Oseltamivir is known as a therapeutic drug for influenza. These therapeutic agents inhibit neuraminidase of influenza virus and make it difficult for influenza virus to be released from infected cells. Although oseltamivir is also used for the prevention of influenza, it does not have the effect of directly inhibiting infection of influenza virus into cells.
インフルエンザウイルスの感染を予防する最も直接的な方法は、マスク等により、物理的にインフルエンザウイルスの体内への侵入を防ぐことである。しかし、目に見えない微細なウイルスが体内に侵入することを完全に防ぐことは困難である。 The most direct method for preventing influenza virus infection is to physically prevent the influenza virus from entering the body using a mask or the like. However, it is difficult to completely prevent invisible fine viruses from entering the body.
ワクチンの投与はインフルエンザの症状の発症の防止及び症状の軽症化に有効であるとされている。しかし、インフルエンザウイルスは頻繁に変異し、多くの亜型が存在する。このため、投与したワクチンの型と流行するインフルエンザウイルスの型とが一致しなければ、大した効果は期待できない。また、仮にワクチンにより血液中にインフルエンザウイルスに対する抗体が形成されたとしても、インフルエンザウイルスが気道の粘膜上皮細胞へ侵入することを阻害するものではない。また、ワクチンの接種にはアレルギー等の副作用のおそれもある。 Vaccine administration is said to be effective in preventing the onset of influenza symptoms and reducing the symptoms. However, influenza viruses are frequently mutated and there are many subtypes. Therefore, if the type of vaccine administered does not match the type of influenza virus that is prevalent, a great effect cannot be expected. Moreover, even if an antibody against influenza virus is formed in the blood by the vaccine, it does not inhibit the influenza virus from entering the mucosal epithelial cells of the respiratory tract. In addition, vaccination may cause side effects such as allergies.
インフルエンザウイルスの変異に影響されにくく且つインフルエンザウイルスの細胞への感染を直接阻害する物質を求めて様々な研究がなされている。人体への安全性という観点から、種々の天然物に由来する成分が検討されている。茶、オレンジ及びカカオ等の種々の植物の抽出物を用いた抗インフルエンザ薬等が開示されている(例えば、特許文献1〜3を参照。)。 Various studies have been conducted in search of substances that are not easily affected by influenza virus mutations and that directly inhibit infection of influenza virus cells. From the viewpoint of safety to the human body, components derived from various natural products have been studied. An anti-influenza drug using various plant extracts such as tea, orange and cacao has been disclosed (see, for example, Patent Documents 1 to 3).
多様なインフルエンザウイルスに対応するためには、普遍的にインフルエンザウイルスの感染を阻害する効果を有する材料の開発が求められている。また、植物由来の成分の多くは、植物からの抽出物であり有効成分が明確に特定されていない。このため、植物の生育環境又は抽出工程のばらつき等により、インフルエンザウイルスの感染を阻害する効果がばらつくおそれがある。また、植物由来の材料であればすべて生体に対して安全であるわけではない。このため、安全性の面からも材料が特定されていることが好ましい。 In order to deal with various influenza viruses, development of materials having an effect of universally inhibiting influenza virus infection is required. In addition, many plant-derived components are extracts from plants, and active ingredients are not clearly specified. For this reason, there exists a possibility that the effect which inhibits the infection of influenza virus may vary by the variation in the growth environment of a plant or an extraction process. Moreover, not all plant-derived materials are safe for living bodies. For this reason, it is preferable that the material is specified also from the viewpoint of safety.
本願発明者らは、生体に対して安全であることが確認されている成分により、インフルエンザウイルスの細胞への感染が阻害できることを見出した。本願は、この知見に基づき、より安全で効果的なインフルエンザウイルスの感染抑制剤を実現できるようにすることを目的とする。 The inventors of the present application have found that a component that has been confirmed to be safe for a living body can inhibit infection of influenza virus into cells. The present application aims to realize a safer and more effective influenza virus infection inhibitor based on this finding.
具体的に、本発明に係るインフルエンザウイルスの感染抑制剤は、ペクチンと、核酸とを含む混合物である。 Specifically, the infection inhibitor for influenza virus according to the present invention is a mixture containing pectin and nucleic acid.
本願発明者は、多糖類であるペクチンと、強く負に帯電した巨大分子である核酸とにより、インフルエンザウイルスの細胞への感染を効率良く抑制できることを見出した。ペクチン及び核酸は、いずれも食品成分であり、生体に対する安全性が高い。また、安定して入手が可能な材料である。また、ノイラミニダーゼの阻害剤とは異なり、インフルエンザウイルスが細胞へ侵入することを防ぐことができるため、インフルエンザウイルスが気道の粘膜上皮細胞等へ感染することを直接に阻害することができる。 The inventor of the present application has found that infection of influenza virus into cells can be efficiently suppressed by pectin which is a polysaccharide and nucleic acid which is a strongly negatively charged macromolecule. Pectin and nucleic acid are both food ingredients and are highly safe for living bodies. In addition, it is a material that can be obtained stably. In addition, unlike the neuraminidase inhibitor, the influenza virus can be prevented from entering the cells, so that the influenza virus can directly inhibit the infection of mucosal epithelial cells of the respiratory tract and the like.
本発明の感染抑制剤において、ペクチンと核酸との混合物の濃度は、0.04%以上とし、ペクチンの濃度は0.01%以上とし、核酸の濃度は0.01%以上とすればよい。 In the infection inhibitor of the present invention, the concentration of the mixture of pectin and nucleic acid may be 0.04% or more, the concentration of pectin may be 0.01% or more, and the concentration of nucleic acid may be 0.01% or more.
本発明の感染抑制剤において、ペクチンは、分子量が50000 Da以上とし、核酸は、分子量が10000 Da以上とすればよい。 In the infection inhibitor of the present invention, the pectin may have a molecular weight of 50,000 Da or more, and the nucleic acid may have a molecular weight of 10,000 Da or more.
本発明の感染抑制剤において、核酸はデオキシリボ核酸とすればよい。
すなわち、本発明は以下の態様を包含する。
[1]ペクチンと、核酸とを含む混合物であることを特徴とするインフルエンザウイルスの感染抑制剤。
[2]前記ペクチンと核酸との混合物の濃度は、0.04%以上であり、前記ペクチンの濃度は0.01%以上であり、前記核酸の濃度は0.01%以上であることを特徴とする[1]に記載の感染抑制剤。
[3]前記ペクチンは、分子量が50000 Da以上であり、前記核酸は、分子量が10000 Da以上であることを特徴とする[1]又は[2]に記載の感染抑制剤。
[4]前記核酸は、デオキシリボ核酸であることを特徴とする[1]〜[3]のいずれかに記載の感染抑制剤。
In the infection inhibitor of the present invention, the nucleic acid may be deoxyribonucleic acid.
That is, the present invention includes the following aspects.
[1] An infection inhibitor for influenza virus, which is a mixture containing pectin and nucleic acid.
[2] The concentration of the pectin and nucleic acid mixture is 0.04% or more, the pectin concentration is 0.01% or more, and the nucleic acid concentration is 0.01% or more. The infection suppressant as described.
[3] The infection inhibitor according to [1] or [2], wherein the pectin has a molecular weight of 50,000 Da or more, and the nucleic acid has a molecular weight of 10000 Da or more.
[4] The infection inhibitor according to any one of [1] to [3], wherein the nucleic acid is deoxyribonucleic acid.
本発明に係る感染抑制剤によれば、インフルエンザウイルスの細胞への感染を効率良く抑制することができる。 According to the infection inhibitor according to the present invention, infection of influenza virus into cells can be efficiently suppressed.
本実施形態に係るインフルエンザウイルスの感染抑制剤は、ペクチンと核酸とを含んでいる。ペクチンは、植物の細胞壁を構成する多糖であり、ほとんどすべての植物に含まれている。このため、由来する植物によりペクチンの構造の細部及び分子量等は異なる。しかし、基本的にはガラクツロン酸のホモポリマーであるホモガラクツロナン及びラムノースとガラクツロン酸とが交互に結合したラムノガラクツロナンを主成分とする。ラムノガラクツロナンのラムノース残基には単糖又は多糖が側鎖として結合している。側鎖を構成する糖は、アラビノース、キシロース、フコース及びラムノース等である。ガラクツロン酸の少なくとも一部はエステル化されている。 The influenza virus infection inhibitor according to this embodiment contains pectin and nucleic acid. Pectin is a polysaccharide that constitutes the cell wall of plants and is contained in almost all plants. For this reason, the details of the structure and molecular weight of pectin vary depending on the plant from which they are derived. However, it is basically composed of homogalacturonan, which is a homopolymer of galacturonic acid, and rhamnogalacturonan in which rhamnose and galacturonic acid are alternately bonded. Monosaccharides or polysaccharides are bonded as side chains to the rhamnose residue of rhamnogalacturonan. Examples of sugars constituting the side chain include arabinose, xylose, fucose, and rhamnose. At least a part of galacturonic acid is esterified.
商業的に入手可能なペクチンとしてリンゴ、柑橘類及び砂糖大根等を原料とするものが知られており、分子量は50000 Da〜360000 Da程度の範囲に分布している。本実施形態の感染抑制剤にはどの様なペクチンであっても用いることができるが、分子量が大きいほどインフルエンザウイルスを捕獲する効果が向上するため、50000 Da以上のものが好ましく、100000 Da以上のものがさらに好ましい。 Commercially available pectin is known from apples, citrus fruits, sugar radishes and the like, and has a molecular weight distributed in the range of about 50,000 Da to 360,000 Da. Any kind of pectin can be used as the infection inhibitor of the present embodiment, but since the effect of capturing influenza virus is improved as the molecular weight increases, those of 50000 Da or more are preferred, and those of 100000 Da or more are preferred. More preferred.
核酸は、五炭糖、リン酸及び塩基から構成された複数のヌクレオチドが結合した高分子である。五炭糖がデオキシリボースであるものをデオキシリボ核酸(DNA)といい、リボースであるものをリボ核酸(RNA)という。DNAに通常含まれる塩基はアデニン、グアニン、シトシン及びチミンである。RNAに通常含まれる塩基はアデニン、グアニン、シトシン及びウラシルである。核酸の各ヌクレオチドは、少なくとも1つの負の電荷を有している。 Nucleic acid is a polymer in which a plurality of nucleotides composed of pentose, phosphate and base are bound. A substance in which the pentose is deoxyribose is called deoxyribonucleic acid (DNA), and a substance in which the pentose is ribose is called ribonucleic acid (RNA). Bases usually contained in DNA are adenine, guanine, cytosine and thymine. The bases normally contained in RNA are adenine, guanine, cytosine and uracil. Each nucleotide of the nucleic acid has at least one negative charge.
ペクチンと核酸とを含む感染抑制剤を用いることによりインフルエンザウイルスの細胞への感染を効率良く抑制することが可能となる。ペクチンと核酸とを混合した感染抑制剤によりインフルエンザウイルスの細胞への感染を効率良く抑制できる理由は明らかではない。インフルエンザウイルスは、ウイルス表面に存在するヘマグルチニンの働きにより細胞に侵入することが知られている。シアル酸と相同性がある水溶性側鎖とウイルスエンベロープと親和する疎水性エステル基とを有するペクチンと、強い負電荷を有する巨大な分子である核酸とが協同して作用することにより、ヘマグルチニンの働きを阻害したり、インフルエンザウイルスの粘膜表面へのアクセスを妨げるのではないかと考えられる。本実施形態の感染抑制剤により、インフルエンザウイルスによる赤血球の凝集反応を阻害できることが確認できており、このことからも、本実施形態の感染抑制剤はヘマグルチニンの働きを阻害していると強く推測される。このように、本実施形態の感染抑制剤は、インフルエンザウイルスの細胞への侵入を阻害している。細胞内において増殖したインフルエンザウイルスが細胞外へ放出されることを阻害するノイラミニダーゼの阻害剤とは異なる機構によりインフルエンザウイルスの細胞への感染を抑制する。 By using an infection inhibitor containing pectin and nucleic acid, it becomes possible to efficiently inhibit infection of influenza virus into cells. It is not clear why infection with influenza virus cells can be efficiently suppressed by an infection inhibitor mixed with pectin and nucleic acid. Influenza virus is known to enter cells by the action of hemagglutinin present on the surface of the virus. A pectin having a water-soluble side chain that is homologous to sialic acid and a hydrophobic ester group that has an affinity for the viral envelope and a nucleic acid that is a large molecule with a strong negative charge cooperate to act as hemagglutinin. It is thought that it may interfere with the function or prevent access to the mucosal surface of influenza virus. It has been confirmed that the infection suppressor of the present embodiment can inhibit the agglutination reaction of erythrocytes caused by influenza virus. From this, it is strongly speculated that the infection suppressor of the present embodiment inhibits the action of hemagglutinin. The Thus, the infection inhibitor of this embodiment inhibits the entry of influenza virus into cells. Influenza cells are prevented from being infected by a mechanism different from that of neuraminidase inhibitors that inhibit the release of influenza virus that has grown intracellularly.
核酸は負電荷を有する巨大分子であればよく、塩基の配列は限定されない。また、糖鎖には影響されずDNAであってもRNAであってもよい。但し、安定性の観点からはDNAの方が好ましい。また、核酸は完全なヌクレオチドだけのポリマーである必要はなく、タンパク質等の他の分子と混合又は結合した状態であっても問題ない。核酸の分子量は、特に問わないが分子量が大きい方がインフルエンザウイルスを捕獲する効果が向上するため、10000 Da以上のものが好ましく、100000 Da以上のものがさらに好ましい。核酸の分子量は高い方が好ましいが、市販されている核酸の分子量は一般的に1000000 Da以下であり、最大でも3000000 Da程度である。この程度の分子量の核酸であっても問題なく使用することができる。 The nucleic acid may be a macromolecule having a negative charge, and the base sequence is not limited. Moreover, it may be DNA or RNA without being affected by the sugar chain. However, DNA is preferable from the viewpoint of stability. In addition, the nucleic acid does not need to be a complete nucleotide-only polymer, and there is no problem even if it is in a mixed or bound state with other molecules such as proteins. The molecular weight of the nucleic acid is not particularly limited, but a larger molecular weight improves the effect of capturing influenza virus, so that it is preferably 10,000 Da or more, more preferably 100,000 Da or more. Although it is preferable that the molecular weight of the nucleic acid is high, the molecular weight of a commercially available nucleic acid is generally 1000000 Da or less, and about 3000000 Da at the maximum. Even nucleic acids of this molecular weight can be used without problems.
ペクチンと核酸との混合物である感染抑制剤の濃度は、0.04%程度以上であることが好ましく、さらに好ましくは0.09%程度以上であることが好ましい。ペクチンと核酸との混合物の濃度が高いほどインフルエンザウイルスの感染を阻害する効果が高くなるが、ペクチンと核酸との混合物の濃度をあまり高くすると、粘度が上昇するため、1%程度以下とすることが好ましく、0.5%程度以下とすることがさらに好ましい。ペクチンと核酸とが共同して作用するため、ペクチンと核酸の一方の濃度が極端に低くない方が好ましく、感染抑制剤中におけるペクチンと核酸との質量比は1:5〜5:1程度とすることが好ましい。ペクチンが多くても、核酸が多くても問題ない。但し、ペクチン及び核酸のそれぞれの濃度が0.01質量%未満とならないことが好ましい。 The concentration of the infection inhibitor that is a mixture of pectin and nucleic acid is preferably about 0.04% or more, more preferably about 0.09% or more. The higher the concentration of the mixture of pectin and nucleic acid, the higher the effect of inhibiting influenza virus infection. However, if the concentration of the mixture of pectin and nucleic acid is too high, the viscosity will increase, so it should be about 1% or less. Is preferable, and about 0.5% or less is more preferable. Since pectin and nucleic acid act together, it is preferable that the concentration of one of pectin and nucleic acid is not extremely low, and the mass ratio of pectin and nucleic acid in the infection inhibitor is about 1: 5 to 5: 1 It is preferable to do. There is no problem even if there are many pectin or nucleic acids. However, it is preferable that the respective concentrations of pectin and nucleic acid are not less than 0.01% by mass.
ペクチンと核酸とを含むインフルエンザウイルスの感染阻害剤を、鼻又は口腔の粘膜細胞に作用させることにより、インフルエンザウイルスの粘膜細胞への感染を効果的に抑制することが可能となる。ペクチンも核酸も生体に対して安全性が高い食品成分であるため、生体に対して用いることに何ら問題はない。このため、本実施形態の感染阻害剤を鼻又は口腔の粘膜細胞に作用させる方法は特に限定されない。例えば、スプレー等により鼻孔又は口腔内へ噴霧したり、吸入器等を用いて鼻孔内又は口腔内へ導入すればよい。また、うがい薬として、口腔内へ導入し粘膜細胞に作用させてもよい。これらの場合には、水を溶媒としたペクチンと核酸とを含む溶液又は懸濁液とすればよいが、溶媒に安定剤、分散剤、乳化剤及び希釈剤等を適宜添加してかまわない。また、本実施形態の感染抑制剤はトローチ又はチューインガム等に添加して口腔内に導入することにより、粘膜細胞に作用させてもよい。口腔又は鼻孔内へ導入する場合には香料等を加えてもよい。 By causing an infection inhibitor of influenza virus containing pectin and nucleic acid to act on mucosal cells of the nose or oral cavity, it is possible to effectively suppress infection of mucosal cells of influenza virus. Since pectin and nucleic acid are food ingredients that are highly safe for the living body, there is no problem in using them for the living body. For this reason, the method of making the infection inhibitor of this embodiment act on a nasal or oral mucosa cell is not specifically limited. For example, it may be sprayed into the nostril or oral cavity by spraying, or introduced into the nostril or oral cavity using an inhaler or the like. Moreover, it may be introduced into the oral cavity as a mouthwash and allowed to act on mucosal cells. In these cases, a solution or suspension containing pectin and nucleic acid using water as a solvent may be used. However, a stabilizer, a dispersant, an emulsifier, a diluent, and the like may be appropriately added to the solvent. Moreover, you may make the infection inhibitor of this embodiment act on a mucosal cell by adding to a troche or chewing gum, etc. and introduce | transducing into an oral cavity. In the case of introduction into the oral cavity or nostril, a fragrance or the like may be added.
また、腸内におけるインフルエンザウイルスの感染を抑制するために、感染抑制剤を経口投与してもよい。この場合には感染抑制剤が腸内に届くような、カプセル剤、錠剤、顆粒又はシロップ等とすればよい。 In addition, in order to suppress infection with influenza virus in the intestine, an infection inhibitor may be administered orally. In this case, a capsule, tablet, granule, syrup or the like may be used so that the infection inhibitor reaches the intestine.
吸入剤、うがい薬、トローチ又はその他の製剤として、粘膜細胞又は腸内細胞等に作用させる場合には、作用する部位における感染抑制剤の濃度が0.04%〜1%程度となるようにすればよく、好ましくは0.09%〜0.5%程度とすればよい。 As an inhalant, mouthwash, troche, or other preparation, when acting on mucosal cells or intestinal cells, the concentration of the infection inhibitor at the site of action should be about 0.04% to 1%. Preferably, it may be about 0.09% to 0.5%.
さらに、雰囲気中に存在するインフルエンザウイルスと感染抑制剤とを作用させてもよい。この場合には、感染抑制剤を噴霧等により大気中に拡散させればよい。感染抑制剤を床面又は手が触れるドアノブ等に局所的に噴霧してもよい。 Furthermore, you may make the influenza virus and infection inhibitor which exist in atmosphere act. In this case, the infection inhibitor may be diffused into the atmosphere by spraying or the like. The infection inhibitor may be sprayed locally on the floor or a door knob touched by the hand.
(一実施例)
以下に、ペクチンと核酸とを含むインフルエンザウイルスの感染抑制剤の一実施例を示す。図1及び2は、赤血球凝集抑制試験の結果を示している。図1及び2において、ペクチンには、柑橘類の果皮由来のペクチン(CP Kelo社製:GENU pectin (citrus) type USP-L、ガラクツロン酸74%以上、メトキシル基率6.7以上)を用いた。核酸には、サケ白子由来のDNA(大和化成社製:DNA-Na、Lot:DN-JD0603)を用いた。感染抑制剤中におけるペクチンとDNAとの質量比は、1:1とした。
(Example)
An example of an influenza virus infection inhibitor containing pectin and nucleic acid is shown below. 1 and 2 show the results of the hemagglutination inhibition test. 1 and 2, pectin derived from citrus peel (CP Kelo: GENU pectin (citrus) type USP-L, galacturonic acid 74% or more, methoxyl group ratio 6.7 or more) was used. For the nucleic acid, DNA derived from salmon white (Daiwa Kasei Co., Ltd .: DNA-Na, Lot: DN-JD0603) was used. The mass ratio of pectin and DNA in the infection inhibitor was 1: 1.
赤血球凝集抑制試験は、一般的な方法に従い以下のようにして行った。単離したモルモット赤血球浮遊液、インフルエンザウイルス(A/PR/8/34(H1N1型)株又はA/Memphis/1/71(H3N2型)株)及びリン酸緩衝生理食塩水(PBS)により所定の濃度とした感染抑制剤を、マイクロタイタープレートのウェルに加えた。所定の時間インキュベーションした後、赤血球の凝集の有無を目視及び顕微鏡下で観察して評価を行った。インフルエンザウイルスを加えていないウェルをネガティブコントロールとした。また、比較例として感染抑制剤に代えてDNAのみを加えて同様の実験を行った。 The hemagglutination inhibition test was performed as follows according to a general method. With the isolated guinea pig erythrocyte suspension, influenza virus (A / PR / 8/34 (H1N1 type) strain or A / Memphis / 1/71 (H3N2 type) strain) and phosphate buffered saline (PBS) Concentrations of infection inhibitors were added to the wells of the microtiter plate. After incubation for a predetermined time, the presence or absence of erythrocyte aggregation was visually and under a microscope for evaluation. Wells to which no influenza virus was added were used as negative controls. As a comparative example, the same experiment was performed by adding only DNA instead of the infection inhibitor.
図1に示すように、インフルエンザウイルスを添加していないネガティブコントロールでは赤血球の凝集は生じず、赤血球の沈降のみが認められた。また、感染抑制剤を加えていないウェル及びDNAのみを加えたウェルでは強い赤血球の凝集が観察された。一方、感染抑制剤を加えたウェルでは明らかに赤血球の凝集が阻害された。H3N2型であるA/Memphis/1/71株に対して若干高い赤血球凝集抑制効果を示したが、H1N1型であるA/PR/8/34株に対してもほぼ同程度の赤血球凝集抑制効果が認められた。このことから、本実施形態の感染抑制剤は抗体と異なりインフルエンザウイルスの型に関係なくヘマグルチニン活性の阻害効果を有していると考えられる。 As shown in FIG. 1, in the negative control to which no influenza virus was added, red blood cell aggregation did not occur, and only red blood cell sedimentation was observed. In addition, strong erythrocyte aggregation was observed in wells to which no infection inhibitor was added and wells to which only DNA was added. On the other hand, erythrocyte aggregation was clearly inhibited in the wells to which infection inhibitors were added. H3N2 type A / Memphis / 1/71 strain showed slightly higher hemagglutination suppression effect, but H1N1 type A / PR / 8/34 strain had almost the same level of hemagglutination suppression effect Was recognized. From this, it is considered that the infection inhibitor of this embodiment has an inhibitory effect on hemagglutinin activity regardless of the type of influenza virus, unlike an antibody.
図3は、ペクチンと核酸とを含む感染抑制剤によるインフルエンザウイルスの感染抑制効果を示している。感染抑制効果の評価は以下のようにして行った。メイディン・ダービー・イヌ腎臓細胞(MDCK細胞)を無血清培地に播種した後、所定の濃度となるように感染抑制剤を添加した。MDCK細胞を37℃で1時間培養した後、インフルエンザウイルスを含む培地に交換し、34℃で20時間培養を行った。インフルエンザウイルスは、A/Memphis/1/71株を用い、所定の濃度の感染抑制剤を添加した無血清培地にて4℃で1時間放置してから使用した。培養後、無血清培地を除去し、MDCK細胞をメタノールを用いて固定した後、抗ウイルス抗体を用いてインフルエンザウイルスに感染した細胞の免疫染色を行い、染色量を測定した。感染抑制剤を加えていない場合の染色量を感染率100%として、染色量から感染抑制率を求めた。核酸を含まないペクチンだけを添加した場合について同様の操作を行い比較例とした。感染抑制剤は、赤血球凝集抑制試験と同じものを用いた。 FIG. 3 shows the influenza virus infection-suppressing effect of an infection-suppressing agent containing pectin and nucleic acid. Evaluation of the infection suppression effect was performed as follows. After inoculating madin, derby, and canine kidney cells (MDCK cells) in a serum-free medium, an infection inhibitor was added to a predetermined concentration. MDCK cells were cultured at 37 ° C. for 1 hour, then replaced with a medium containing influenza virus, and cultured at 34 ° C. for 20 hours. The influenza virus was A / Memphis / 1/71 strain, which was used after being allowed to stand at 4 ° C. for 1 hour in a serum-free medium supplemented with a predetermined concentration of infection inhibitor. After the culture, the serum-free medium was removed, and MDCK cells were fixed with methanol, and then the cells infected with influenza virus were immunostained with an antiviral antibody, and the amount of staining was measured. The infection suppression rate was calculated from the staining amount, assuming that the staining amount when no infection inhibitor was added was 100% infection rate. The same operation was performed for the case where only pectin containing no nucleic acid was added, and was used as a comparative example. The same infection inhibitor as that used in the hemagglutination inhibition test was used.
図3に示すように、核酸を含まないペクチンだけの場合には、0.2%程度の濃度において50%程度の感染抑制率を示した。一方、核酸とペクチンとを含む感染抑制剤の場合には、0.04%程度の濃度において50%程度の感染抑制率を示し、0.09%程度の濃度において80%程度の感染抑制率を示した。また。0.25%程度の濃度における感染抑制率は96%程度となり、ペクチン単独の場合よりも遙かに高い感染抑制効果を示した。 As shown in FIG. 3, in the case of only pectin containing no nucleic acid, the infection suppression rate was about 50% at a concentration of about 0.2%. On the other hand, in the case of the infection inhibitor containing nucleic acid and pectin, an infection inhibition rate of about 50% was exhibited at a concentration of about 0.04%, and an infection inhibition rate of about 80% was exhibited at a concentration of about 0.09%. Also. The infection suppression rate at a concentration of about 0.25% was about 96%, indicating a much higher infection suppression effect than pectin alone.
本発明に係る感染抑制剤は、効率良くインフルエンザウイルスの細胞への感染を抑制することができ、インフルエンザウイルスの感染抑制剤等として有用である。 The infection inhibitor according to the present invention can efficiently inhibit infection of influenza virus cells, and is useful as an influenza virus infection inhibitor and the like.
Claims (3)
核酸と
を含む混合物を含み、
前記ペクチンと核酸との混合物の濃度は、0.04%以上であり、前記ペクチンの濃度は0.01%以上であり、前記核酸の濃度は0.01%以上であり、
水を溶媒とした溶液若しくは懸濁液である、
腸内、鼻若しくは口腔の粘膜細胞に作用させるための、大気中に拡散させるための、又は床面若しくは手が触れる箇所に局所的に噴霧するための、インフルエンザウイルスの感染抑制剤。 With pectin,
A mixture comprising a nucleic acid and
The concentration of the mixture of pectin and nucleic acid is 0.04% or more, the concentration of pectin is 0.01% or more, and the concentration of nucleic acid is 0.01% or more,
A solution or suspension using water as a solvent,
Influenza virus infection inhibitor for acting on mucosal cells of the intestine, nose or oral cavity, for diffusing in the atmosphere, or for spraying locally on the floor surface or a place where the hand touches.
核酸と
を含む混合物を含み、
前記ペクチンと核酸との混合物の濃度は、0.04%以上であり、前記ペクチンの濃度は0.01%以上であり、前記核酸の濃度は0.01%以上である、
トローチ、チューインガム、カプセル剤、錠剤、顆粒若しくはシロップに添加して口腔内又は腸内の粘膜細胞に作用させるための、インフルエンザウイルスの感染抑制剤。 With pectin,
A mixture comprising a nucleic acid and
The concentration of the mixture of pectin and nucleic acid is 0.04% or more, the concentration of pectin is 0.01% or more, and the concentration of nucleic acid is 0.01% or more.
An influenza virus infection suppressant, which is added to troches, chewing gums, capsules, tablets, granules or syrups and acts on mucosal cells in the oral cavity or intestine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016204967A JP6317798B2 (en) | 2016-10-19 | 2016-10-19 | Influenza virus infection inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016204967A JP6317798B2 (en) | 2016-10-19 | 2016-10-19 | Influenza virus infection inhibitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015030727A Division JP6211023B2 (en) | 2015-02-19 | 2015-02-19 | Influenza virus infection inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017019861A true JP2017019861A (en) | 2017-01-26 |
JP6317798B2 JP6317798B2 (en) | 2018-04-25 |
Family
ID=57888852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016204967A Active JP6317798B2 (en) | 2016-10-19 | 2016-10-19 | Influenza virus infection inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6317798B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512325A (en) * | 1999-10-19 | 2003-04-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | Compositions for preventing and treating cold and flu-like symptoms, and methods of using them |
WO2004100966A1 (en) * | 2003-05-16 | 2004-11-25 | Bbk Bio Corporation | Preparation for preventing contact of pathogenic matter with living organism |
JP2005343836A (en) * | 2004-06-04 | 2005-12-15 | Lotte Co Ltd | Anti-influenza virus agent, and infection inhibiting article containing the same and food and drink |
-
2016
- 2016-10-19 JP JP2016204967A patent/JP6317798B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003512325A (en) * | 1999-10-19 | 2003-04-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | Compositions for preventing and treating cold and flu-like symptoms, and methods of using them |
WO2004100966A1 (en) * | 2003-05-16 | 2004-11-25 | Bbk Bio Corporation | Preparation for preventing contact of pathogenic matter with living organism |
JP2005343836A (en) * | 2004-06-04 | 2005-12-15 | Lotte Co Ltd | Anti-influenza virus agent, and infection inhibiting article containing the same and food and drink |
Non-Patent Citations (1)
Title |
---|
GREE RH, ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 86, JPN6014031018, 1947, pages 55-64 * |
Also Published As
Publication number | Publication date |
---|---|
JP6317798B2 (en) | 2018-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5996837B2 (en) | Influenza virus infection inhibitor | |
Hoseini et al. | Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection | |
JP2022115999A (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
JP2012176990A5 (en) | ||
EA013468B1 (en) | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone | |
WO2019046426A1 (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
EP3046558A2 (en) | Deoxynojirimycin derivatives and methods of their using | |
Bhat et al. | Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches | |
EP4171580A1 (en) | Antiviral pharmaceutical composition | |
Baaten et al. | Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue | |
WO2006084198A2 (en) | Nitroxides for use in treating or preventing immunological diseases | |
Mazilu et al. | Thrombosis and Haemostasis challenges in COVID-19–Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review | |
JP6317798B2 (en) | Influenza virus infection inhibitor | |
JP6211023B2 (en) | Influenza virus infection inhibitor | |
Grygiel-Gorniak | Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic | |
CN102711463A (en) | Hypersulfated disaccharide formulations | |
CN104069106A (en) | Application of benzamide compound in preparation of medicine for activating latent human immunodeficiency virus | |
WO2017201030A1 (en) | Methods of treating viral infection | |
US20220125827A1 (en) | Application of Sulfated Polysaccharides in Resisting novel Coronavirus | |
US20140199346A1 (en) | Therapeutic agent for influenza virus infection diseases | |
KR20120091157A (en) | Arabinogalactan for enhancing the adaptive immune response | |
Rios-Ibarra et al. | Nanoparticle‑based antiviral strategies to combat the influenza virus | |
WO2003051301A2 (en) | USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY | |
RU2580305C1 (en) | ANTIVIRAL AGENT BASED ON DRY EXTRACT OF LICHEN Cetraria islandica | |
Bălan | Integrative bioinformatic analysis of SARs-CoV-2 data |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180330 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6317798 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |